PALL CORPORATION

SERVICE PLAN
WEBINAR


Maintain optimal mixing performance with Pall’s services

Tuesday, 15th of November 2022 at 15:30 CET

Webinars Available

Maintain optimal mixing performance with Pall’s services

  • Tuesday, 15th of November 2022 | 15:30-16:00 CET
Duration:
30 minutes
Summary:

Learn more about maintenance and calibration solutions to help you maintain your mixing equipment.

Participants will be able to get information on:

  • Preventive maintenance
  • Calibration
  • Maintenance recommendations
  • Service plans
...

Speaker:

Helena Averty

Pall Corporation

Service Product Manager – Mixers & Large-scale bioreactors

Helena holds an MBA degree from HEC Paris, France. She joined Pall Corporation as a Service Product Manager in 2022 and is part of the General Manager Development Program at Danaher.
...

Speaker:

Nolan Bishop

Pall Corporation

Product Support Engineer

Nolan is a Product Support Engineer with 2 years of experience at Pall. He currently supports the mixer and Palltronic® product lines as the service subject matter expert. Noland graduated from Boston University in 2020 with a degree in Mechanical Engineering and he lives in New York City
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Covid-19 and the Vaccines Route for Eradicating the Disease

  • Tuesday, Oct 06- 08:00 PDT | 11:00 EDT | 16:00 BST | 17:00 CEST
  • Thursday, Oct 22 - 08:00 CEST | 11:30 IST | 14:00 SGT | 15:00 JST
Duration:
2 Hours
Summary:

This diversity in the type of vaccine antigen, along with the inherent variation in the targets, have created challenges for vaccine manufacturers when compared to a relatively small number of platform processes that exist for other biotherapeutic production processes

Accelerating vaccine development and manufacturing by coupling research advances in vaccine technology with systems that support agility through a Quality by Design approach is critical to deliver life-saving immunizations to those in need globally.

Each class of vaccine presents specific process development and manufacturing challenges, and the scale of production varies depending upon the targeted disease. As a result, there is no single vaccine manufacturing approach.

There are, however, flexible technologies that can meet each of the challenges during process development and at GMP scale. These customizable technologies can be applied separately but can also be combined to design robust, integrated, flexible platforms that support rapid process development and safeguard the quality of life-protecting vaccines, where closed-systems and aseptic processing is essential.

...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.
...

Speaker:

David Johnson

Pall Biotech

Senior Global Product Manager, Continuous Purification

Sudhakar Nagaraj has been in the Pharmaceutical industry for over 17 years and joined Pall during 2006 in the Scientific Laboratory Services (SLS) organization.

Register Now

If you would like to attend a webinar, please complete the form below and click the “Register Now" button.